Across TCGA pan-cancer cohorts, C1orf52 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C1orf52 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher C1orf52 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C1orf52 expression acts as an unfavorable survival marker.
COAD, HNSC, and LUSC are the cancer types where C1orf52 Mutation most reproducibly stratifies survival.